… Two patients had CMV viremia during treatment but none experienced CMV disease. In
conclusion, a valganciclovir-dosing algorithm that adjusted for body surface area and renal …

… on the four patients treated with valganciclovir in a clinical setting at our transplant center and
… performed with only single kidney and single liver transplant recipients as well as in all 61 …

… valganciclovir dosing regimens and the potential benefits of individualized dose adjustments
in children following organ transplantation. … in pediatric SOT recipients aged six months …

… pharmacodynamics after valganciclovir administration, to … of adult solid organ transplant
recipients receiving valganciclovir … in plasma from patients receiving oral valganciclovir therapy. …

… valganciclovir (VGCV) dosing strategy for cytomegalovirus (CMV) prophylaxis and treatment
in pediatric organ transplant recipients. … VGCV dosing among pediatric transplant centers. …

… , respectively), and covariate analyses showed no apparent effect of gender, age or race
on the extent of ganciclovir exposure after valganciclovir administration. There was no clear …

… of ganciclovir after oral administration of valganciclovir in SOT recipients was successfully
… its oral administration was unsuccessful. There were only half the number of patients in the …

… optimal valganciclovir dosing protocol for CMV prophylaxis in infants and young children
with solid-organ transplants have not yet been clarified. The current dosing recommendation of …

… of prophylaxis) following administration of valganciclovir 900 mg once daily or oral
ganciclovir 1000 mg three times daily in solid organ transplant recipients. Dosage was adjusted …

… valganciclovir in solid organ transplant patients with cytomegalovirus. Patients received
ganciclovir at 5 mg/kg of body … of valganciclovir (16 days), both twice daily with dose adjustment …